Nuveen LLC Purchases Shares of 24,990 Telomir Pharmaceuticals, Inc. $TELO

Nuveen LLC purchased a new stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 24,990 shares of the company’s stock, valued at approximately $81,000. Nuveen LLC owned approximately 0.08% of Telomir Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its position in Telomir Pharmaceuticals by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 91,353 shares of the company’s stock valued at $295,000 after purchasing an additional 19,058 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in Telomir Pharmaceuticals in the 4th quarter valued at about $103,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Telomir Pharmaceuticals by 279.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock valued at $44,000 after purchasing an additional 7,879 shares in the last quarter. Gotham Asset Management LLC acquired a new stake in Telomir Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, Bank of America Corp DE raised its position in Telomir Pharmaceuticals by 283.9% in the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after purchasing an additional 10,880 shares in the last quarter.

Telomir Pharmaceuticals Price Performance

TELO stock opened at $1.24 on Monday. The firm has a market capitalization of $40.03 million, a P/E ratio of -2.30 and a beta of -0.72. The business’s 50-day moving average is $1.53 and its two-hundred day moving average is $2.41. Telomir Pharmaceuticals, Inc. has a 1 year low of $1.12 and a 1 year high of $8.40.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.09). On average, analysts expect that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current year.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.